Physician profile
Robert Gerstenbluth
NPI 1326078387
$4,510.59
in general payments reported to CMS, 2019-2025
29 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $259 · 2022: $667 · 2023: $477 · 2024: $1,003 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369 · Education: $92.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.66 |
| Education | $92.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $793.35 | 2021-2025 | Xtandi, Veozah |
| Janssen Biotech, INC. | $538.29 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Sumitomo Pharma America, INC. | $419.45 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $357.27 | 2021-2024 | Greenlight Xps, Spaceoar Vue System - 10ml |
| Merck Sharp & Dohme LLC | $265.34 | 2023-2025 | Lynparza, Keytruda |
| Ferring Pharmaceuticals INC. | $242.77 | 2025 | Adstiladrin |
| Teleflex LLC | $230.76 | 2021-2025 | Urolift, Barrigel |
| Tolmar, INC. | $212.42 | 2023-2025 | Jatenzo, Eligard |
| Urovant Sciences INC | $211.41 | 2022 | |
| Endo Pharmaceuticals INC. | $169.26 | 2022-2024 | Aveed, Xiaflex |
| Abbvie INC. | $152.88 | 2022-2025 | |
| Axonics, INC. | $151.97 | 2020-2024 | Axonics, Bulkamid |
| Pfizer INC. | $139.29 | 2020-2025 | |
| Coloplast Corp | $119.60 | 2022-2025 | |
| Endo USA, INC. | $112.68 | 2025 | Xiaflex, Aveed |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $62.13 | 2025 | |
| 180 Medical, INC. | $56.43 | 2022-2023 | Gentlecath |
| Procept Biorobotics Corporation | $48.28 | 2024-2025 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $29.50 | 2025 | Provenge |
| Amgen INC. | $25.62 | 2022 | |
| Immunitybio, INC. | $24.57 | 2025 | |
| Laborie Medical Technologies Corp. | $24.52 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Myriad Genetic Laboratories, INC. | $22.74 | 2025 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $21.76 | 2025 | Lynparza |
| Ambu INC. | $19.66 | 2025 | |
| Dentsply Ih Ab | $16.15 | 2023 | Lofric |
| Antares Pharma, INC. | $15.22 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $14.21 | 2022 | |
| Rochester Medical Corporation | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gerstenbluth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.